Published in J Cell Biochem on January 01, 2015
Integration of Chinese Herbal Medicine Therapy Improves Survival of Patients With Chronic Lymphocytic Leukemia: A Nationwide Population-Based Cohort Study. Medicine (Baltimore) (2016) 0.78
Ganoderic Acid A Metabolites and Their Metabolic Kinetics. Front Pharmacol (2017) 0.75
Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer (1972) 35.74
Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin (2012) 14.47
Apoptosis. Its significance in cancer and cancer therapy. Cancer (1994) 6.71
Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest (2008) 3.37
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest (2014) 3.06
The proapoptotic BH3-only protein bim is expressed in hematopoietic, epithelial, neuronal, and germ cells. Am J Pathol (2000) 2.53
Role of cytochrome c and dATP/ATP hydrolysis in Apaf-1-mediated caspase-9 activation and apoptosis. EMBO J (1999) 2.45
T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res (2012) 2.43
The role of BH3-only protein Bim extends beyond inhibiting Bcl-2-like prosurvival proteins. J Cell Biol (2009) 2.27
Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One (2012) 1.70
Bim-targeted cancer therapy: a link between drug action and underlying molecular changes. Mol Cancer Ther (2009) 1.56
Ganoderma lucidum and its pharmaceutically active compounds. Biotechnol Annu Rev (2007) 1.55
Myeloid-derived suppressor cells in cancer: recent progress and prospects. Immunol Cell Biol (2013) 1.50
Finding the sweet spot: the role of nature and nurture in medicinal chemistry. Nat Rev Drug Discov (2012) 1.43
Absence of gamma-interferon-inducible lysosomal thiol reductase in melanomas disrupts T cell recognition of select immunodominant epitopes. J Exp Med (2002) 1.38
Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer. J Immunother Cancer (2013) 1.35
Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation. Leukemia (2012) 1.27
Effects of active and inactive phospholipase D2 on signal transduction, adhesion, migration, invasion, and metastasis in EL4 lymphoma cells. Mol Pharmacol (2008) 1.23
The severe acute respiratory syndrome coronavirus nucleocapsid protein is phosphorylated and localizes in the cytoplasm by 14-3-3-mediated translocation. J Virol (2005) 1.15
Apoptosis-modulating drugs for improved cancer therapy. Eur Surg Res (2012) 1.12
Gamma-IFN-inducible-lysosomal thiol reductase modulates acidic proteases and HLA class II antigen processing in melanoma. Cancer Immunol Immunother (2008) 1.12
Deficient antigen-presenting cell function in multiple genetic complementation groups of type II bare lymphocyte syndrome. J Clin Invest (1995) 1.09
Ganoderic acids suppress growth and invasive behavior of breast cancer cells by modulating AP-1 and NF-kappaB signaling. Int J Mol Med (2008) 1.07
Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines. Cancer Immunol Immunother (2011) 1.07
Ganoderic acid DM, a natural triterpenoid, induces DNA damage, G1 cell cycle arrest and apoptosis in human breast cancer cells. Fitoterapia (2011) 1.06
Myeloid-derived suppressor cells: the dark knight or the joker in viral infections? Immunol Rev (2013) 1.05
Structural requirements for recognition of the HLA-Dw14 class II epitope: a key HLA determinant associated with rheumatoid arthritis. Proc Natl Acad Sci U S A (1990) 1.03
Studies on the immuno-modulating and anti-tumor activities of Ganoderma lucidum (Reishi) polysaccharides. Bioorg Med Chem (2004) 1.02
Requirement of Apaf-1 for mitochondrial events and the cleavage or activation of all procaspases during genotoxic stress-induced apoptosis. Biochem J (2007) 0.99
Antitumor and antimetastatic effects on liver of triterpenoid fractions of Ganoderma lucidum: mechanism of action and isolation of an active substance. Anticancer Res (2003) 0.99
Cysteinylation of MHC class II ligands: peptide endocytosis and reduction within APC influences T cell recognition. J Immunol (2001) 0.97
Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways. Cancer Res (2013) 0.96
Advances in the molecular pathobiology of B-lymphoblastic leukemia. Hum Pathol (2012) 0.95
Defects in HLA class II antigen presentation in B-cell lymphomas. Leuk Lymphoma (2008) 0.95
Importance of relative dose intensity in chemotherapy for diffuse large B-cell lymphoma. J Clin Exp Hematop (2011) 0.95
State of the art in the treatment of Hodgkin lymphoma. Nat Rev Clin Oncol (2012) 0.95
T cell recognition of major histocompatibility complex class II complexes with invariant chain processing intermediates. J Exp Med (1995) 0.93
Ganoderma lucidum (Reishi) in cancer treatment. Integr Cancer Ther (2003) 0.93
Structure and function of the hematopoietic cancer niche: focus on chronic lymphocytic leukemia. Front Biosci (Schol Ed) (2012) 0.91
Natural diterpenoid compound elevates expression of Bim protein, which interacts with antiapoptotic protein Bcl-2, converting it to proapoptotic Bax-like molecule. J Biol Chem (2011) 0.90
HLA class II antigen presentation by prostate cancer cells. Prostate Cancer Prostatic Dis (2007) 0.89
Mechanisms regulating enhanced human leukocyte antigen class II-mediated CD4 + T cell recognition of human B-cell lymphoma by resveratrol. Leuk Lymphoma (2011) 0.89
Inhibition of the JAK-STAT3 signaling pathway by ganoderic acid A enhances chemosensitivity of HepG2 cells to cisplatin. Planta Med (2012) 0.87
Ganoderic acids suppress growth and angiogenesis by modulating the NF-κB signaling pathway in breast cancer cells. Int J Clin Pharmacol Ther (2012) 0.86
Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy: involved-field versus involved-node radiotherapy. Cancer (2012) 0.85
HLA class II defects in Burkitt lymphoma: bryostatin-1-induced 17 kDa protein restores CD4+ T-cell recognition. Clin Dev Immunol (2011) 0.85
Effect of Ganoderma on drug-sensitive and multidrug-resistant small-cell lung carcinoma cells. Cancer Lett (2009) 0.83
Disruption of HLA class II antigen presentation in Burkitt lymphoma: implication of a 47,000 MW acid labile protein in CD4+ T-cell recognition. Immunology (2014) 0.83
Invariant chain modulates HLA class II protein recycling and peptide presentation in nonprofessional antigen presenting cells. Cell Immunol (2007) 0.83
Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement. Cancer Res (2007) 0.83
Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancer. Immunotargets Ther (2012) 0.82
A possible cross-talk between autophagy and apoptosis in generating an immune response in melanoma. Apoptosis (2012) 0.82
Suppression of proliferation and oxidative stress by extracts of Ganoderma lucidum in the ovarian cancer cell line OVCAR-3. Int J Mol Med (2011) 0.82
Enhancement of HLA class II-restricted CD4+ T cell recognition of human melanoma cells following treatment with bryostatin-1. Cell Immunol (2011) 0.81
Loss of heterozygosity, a frequent but a non-exclusive mechanism responsible for HLA dysregulation in non-Hodgkin's lymphomas. Br J Haematol (2004) 0.80
Cytotoxic and pro-apoptotic effects of novel ganoderic acid derivatives on human cervical cancer cells in vitro. Eur J Pharmacol (2012) 0.80
Direct (13)C NMR detection in HPLC hyphenation mode: analysis of Ganoderma lucidum terpenoids. J Nat Prod (2012) 0.79
Defining the mechanisms of CD8 T-cell tumor tolerance. Immunotherapy (2011) 0.79
Seek and destroy: the use of natural compounds for targeting the molecular roots of cancer. Curr Drug Targets (2012) 0.78
Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS One (2010) 1.95
Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest (2005) 1.70
A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol (2008) 1.70
Cannabinoids as novel anti-inflammatory drugs. Future Med Chem (2009) 1.58
Antigen-specific memory B-cell responses to Vibrio cholerae O1 infection in Bangladesh. Infect Immun (2009) 1.56
A hexane fraction of American ginseng suppresses mouse colitis and associated colon cancer: anti-inflammatory and proapoptotic mechanisms. Cancer Prev Res (Phila) (2012) 1.55
A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration. Invest Ophthalmol Vis Sci (2009) 1.54
Complement function in mAb-mediated cancer immunotherapy. Trends Immunol (2004) 1.52
Resveratrol (trans-3,5,4'-trihydroxystilbene) induces silent mating type information regulation-1 and down-regulates nuclear transcription factor-kappaB activation to abrogate dextran sulfate sodium-induced colitis. J Pharmacol Exp Ther (2009) 1.48
Resveratrol suppresses colitis and colon cancer associated with colitis. Cancer Prev Res (Phila) (2010) 1.48
Effects of a novel orally administered calpain inhibitor SNJ-1945 on immunomodulation and neurodegeneration in a murine model of multiple sclerosis. J Neurochem (2014) 1.47
Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. J Clin Invest (2003) 1.46
Oxidative stress renders retinal pigment epithelial cells susceptible to complement-mediated injury. J Biol Chem (2009) 1.45
A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer. Blood (2012) 1.45
Resveratrol (trans-3,5,4'-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. Mol Pharmacol (2007) 1.43
Cannabinoid receptor activation leads to massive mobilization of myeloid-derived suppressor cells with potent immunosuppressive properties. Eur J Immunol (2010) 1.39
Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kappaB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation. J Immunol (2004) 1.35
Activation of aryl hydrocarbon receptor (AhR) leads to reciprocal epigenetic regulation of FoxP3 and IL-17 expression and amelioration of experimental colitis. PLoS One (2011) 1.34
Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells. Mol Pharmacol (2008) 1.31
Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J Immunol (2005) 1.28
Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression. Mol Pharmacol (2006) 1.27
Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood (2002) 1.24
Effects of active and inactive phospholipase D2 on signal transduction, adhesion, migration, invasion, and metastasis in EL4 lymphoma cells. Mol Pharmacol (2008) 1.23
A complement-dependent balance between hepatic ischemia/reperfusion injury and liver regeneration in mice. J Clin Invest (2009) 1.21
Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology (2009) 1.20
CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents. Clin Immunol (2006) 1.20
Essential roles of grp94 in gut homeostasis via chaperoning canonical Wnt pathway. Proc Natl Acad Sci U S A (2013) 1.19
Complement plays an important role in spinal cord injury and represents a therapeutic target for improving recovery following trauma. Am J Pathol (2006) 1.17
Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J Pharmacol Exp Ther (2002) 1.17
American ginseng suppresses inflammation and DNA damage associated with mouse colitis. Carcinogenesis (2008) 1.17
Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer Res (2005) 1.16
Mapping the intermedilysin-human CD59 receptor interface reveals a deep correspondence with the binding site on CD59 for complement binding proteins C8alpha and C9. J Biol Chem (2011) 1.12
Gamma-IFN-inducible-lysosomal thiol reductase modulates acidic proteases and HLA class II antigen processing in melanoma. Cancer Immunol Immunother (2008) 1.12
Crystal structure of CD59: implications for molecular recognition of the complement proteins C8 and C9 in the membrane-attack complex. Acta Crystallogr D Biol Crystallogr (2007) 1.11
A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice. J Immunol (2007) 1.10
Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice. J Immunol (2009) 1.09
Complement-dependent P-selectin expression and injury following ischemic stroke. J Immunol (2006) 1.09
Defining the CD59-C9 binding interaction. J Biol Chem (2006) 1.09
Cutting edge: induction of the antigen-processing enzyme IFN-gamma-inducible lysosomal thiol reductase in melanoma cells Is STAT1-dependent but CIITA-independent. J Immunol (2004) 1.09
Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice. J Immunol (2008) 1.07
Role of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol. PLoS One (2011) 1.05
Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(-/-) mice by attenuating the activation of T cells and promoting their apoptosis. Toxicol Appl Pharmacol (2011) 1.05
Targeted inhibition of complement activation prevents features of preeclampsia in mice. Kidney Int (2010) 1.04
Endocannabinoids and immune regulation. Pharmacol Res (2009) 1.04
The alternative complement pathway propagates inflammation and injury in murine ischemic stroke. J Immunol (2012) 1.03
American ginseng preferentially suppresses STAT/iNOS signaling in activated macrophages. J Ethnopharmacol (2009) 1.03
Primary peripheral T cells become susceptible to 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated apoptosis in vitro upon activation and in the presence of dendritic cells. Mol Pharmacol (2008) 1.03
Pathogenic natural antibodies propagate cerebral injury following ischemic stroke in mice. J Immunol (2011) 1.02
Role of dioxin response element and nuclear factor-kappaB motifs in 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated regulation of Fas and Fas ligand expression. Mol Pharmacol (2006) 1.02
CD44 mobilization in allogeneic dendritic cell-T cell immunological synapse plays a key role in T cell activation. J Leukoc Biol (2008) 1.02
CR2-mediated targeting of complement inhibitors: bench-to-bedside using a novel strategy for site-specific complement modulation. Adv Exp Med Biol (2013) 1.01
Complement inhibitors targeted to the proximal tubule prevent injury in experimental nephrotic syndrome and demonstrate a key role for C5b-9. J Immunol (2005) 1.01
Ginkgo biloba extract EGb 761 has anti-inflammatory properties and ameliorates colitis in mice by driving effector T cell apoptosis. Carcinogenesis (2008) 1.01
American ginseng suppresses colitis through p53-mediated apoptosis of inflammatory cells. Cancer Prev Res (Phila) (2010) 1.01
Multiple anti-inflammatory pathways triggered by resveratrol lead to amelioration of staphylococcal enterotoxin B-induced lung injury. Br J Pharmacol (2012) 1.01
Increased calpain correlates with Th1 cytokine profile in PBMCs from MS patients. J Neuroimmunol (2007) 1.01
Delta9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria. Mol Cancer Res (2006) 1.00
Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injury. Kidney Int (2011) 1.00
Memory T-cell responses to Vibrio cholerae O1 infection. Infect Immun (2009) 0.99
Complement regulates TLR4-mediated inflammatory responses during intestinal ischemia reperfusion. Mol Immunol (2010) 0.99
Role of cytokines as a double-edged sword in sepsis. In Vivo (2013) 0.98
The alternative pathway is required, but not alone sufficient, for retinal pathology in mouse laser-induced choroidal neovascularization. Mol Immunol (2011) 0.98
Targeted deletion of CD44v7 exon leads to decreased endothelial cell injury but not tumor cell killing mediated by interleukin-2-activated cytolytic lymphocytes. J Biol Chem (2003) 0.97
An essential role of Nrf2 in American ginseng-mediated anti-oxidative actions in cardiomyocytes. J Ethnopharmacol (2010) 0.97
Role of CD44 in the differentiation of Th1 and Th2 cells: CD44-deficiency enhances the development of Th2 effectors in response to sheep RBC and chicken ovalbumin. J Immunol (2009) 0.97
Increased expression of B cell-associated regulatory cytokines by glatiramer acetate in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol (2010) 0.96
Targeting cannabinoid receptors to treat leukemia: role of cross-talk between extrinsic and intrinsic pathways in Delta9-tetrahydrocannabinol (THC)-induced apoptosis of Jurkat cells. Leuk Res (2005) 0.96
Burkitt lymphoma: pathogenesis and immune evasion. J Oncol (2010) 0.96
Resveratrol prevents endothelial cells injury in high-dose interleukin-2 therapy against melanoma. PLoS One (2012) 0.95
The alternative and terminal pathways of complement mediate post-traumatic spinal cord inflammation and injury. Am J Pathol (2010) 0.95
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces Fas-dependent activation-induced cell death in superantigen-primed T cells. Arch Toxicol (2002) 0.95
A key role of microRNA-29b for the suppression of colon cancer cell migration by American ginseng. PLoS One (2013) 0.95
Blockade of hyaluronan inhibits IL-2-induced vascular leak syndrome and maintains effectiveness of IL-2 treatment for metastatic melanoma. J Immunol (2007) 0.95
Role of CD44 in activation-induced cell death: CD44-deficient mice exhibit enhanced T cell response to conventional and superantigens. Int Immunol (2002) 0.95
Use of natural AhR ligands as potential therapeutic modalities against inflammatory disorders. Nutr Rev (2013) 0.95
CD1d-independent activation of invariant natural killer T cells by staphylococcal enterotoxin B through major histocompatibility complex class II/T cell receptor interaction results in acute lung injury. Infect Immun (2011) 0.95
Defects in HLA class II antigen presentation in B-cell lymphomas. Leuk Lymphoma (2008) 0.95
Role of resveratrol-induced CD11b(+) Gr-1(+) myeloid derived suppressor cells (MDSCs) in the reduction of CXCR3(+) T cells and amelioration of chronic colitis in IL-10(-/-) mice. Brain Behav Immun (2011) 0.94
CD4+ T cells and complement independently mediate graft ischemia in the rejection of mouse orthotopic tracheal transplants. Circ Res (2011) 0.94
Insights into the human CD59 complement binding interface toward engineering new therapeutics. J Biol Chem (2005) 0.94
Ketamine-xylazine-acepromazine compared with isoflurane for anesthesia during liver transplantation in rodents. J Am Assoc Lab Anim Sci (2010) 0.93
Role of CD44 and hyaluronic acid (HA) in activation of alloreactive and antigen-specific T cells by bone marrow-derived dendritic cells. J Immunother (2003) 0.93
HLA-DM negatively regulates HLA-DR4-restricted collagen pathogenic peptide presentation and T cell recognition. Eur J Immunol (2008) 0.93
Evidence for induction of apoptosis in T cells from murine fetal thymus following perinatal exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Toxicol Sci (2004) 0.93
Double potential interval and transisthmus conduction time for prediction of cavotricuspid isthmus block after ablation of typical atrial flutter. J Interv Card Electrophysiol (2002) 0.92
The C5 convertase is not required for activation of the terminal complement pathway in murine experimental cerebral malaria. J Biol Chem (2012) 0.92
Taming the beast within: resveratrol suppresses colitis and prevents colon cancer. Aging (Albany NY) (2010) 0.92
Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection. Int J Cancer (2008) 0.92
A tumor-expressed inhibitor of the early but not late complement lytic pathway enhances tumor growth in a rat model of human breast cancer. Cancer Res (2002) 0.92
Targeted complement inhibitors protect against posttransplant cardiac ischemia and reperfusion injury and reveal an important role for the alternative pathway of complement activation. J Immunol (2010) 0.92
Role of CD4(+)CD25(+) T regulatory cells in IL-2-induced vascular leak. Int Immunol (2006) 0.92
Mechanistic insight into the ability of American ginseng to suppress colon cancer associated with colitis. Carcinogenesis (2010) 0.92
Development of immunoglobulin M memory to both a T-cell-independent and a T-cell-dependent antigen following infection with Vibrio cholerae O1 in Bangladesh. Infect Immun (2009) 0.91
Unique SNP in CD44 intron 1 and its role in breast cancer development. Anticancer Res (2010) 0.91
Robust antimicrobial compounds and polymers derived from natural resin acids. Chem Commun (Camb) (2011) 0.90
Modulation of protective T cell immunity by complement inhibitor expression on tumor cells. Cancer Res (2008) 0.90
miR-155 deficiency protects mice from experimental colitis by reducing T helper type 1/type 17 responses. Immunology (2014) 0.90